姜黄 (Curcuma longa L.) 提取物 (CLE) 已被证明具有多种药理特性，广泛用于亚洲传统医学。在此，我们评估了 CLE 对 BALB/c 小鼠和 A549 细胞气道炎症的影响，以阐明其潜在机制。通过给予卵清蛋白（OVA）建立哮喘小鼠模型。从第 18 天到第 23 天，每天口服 CLE（100 或 300 mg/kg/天），并使用地塞米松（3 mg/kg/天）作为阳性对照。使用重组肿瘤坏死因子-α 刺激人气道上皮细胞 A549。 CLE100和CLE400组的嗜酸性粒细胞计数、细胞因子水平和免疫球蛋白-E水平显着下调。此外，CLE 给药剂量依赖性地抑制肺组织中的氧化应激和气道炎症。 CLE 给药抑制丝裂原激活蛋白激酶 (MAPK) 的磷酸化以及基质金属蛋白酶 (MMP)-9 的表达和活性。在体外，CLE 治疗降低了促炎细胞因子的 mRNA 水平、MAPK 磷酸化以及 MMP-2 和 MMP-9 的表达和活性。此外，50 µg/mL CLE 和 2.5 µg/mL 姜黄素也显示出相似的抗炎作用。总的来说，我们的研究结果表明，CLE 可以通过氧化应激驱动的 MAPK/MMP 信号传导抑制哮喘小鼠和 A549 细胞的气道炎症，这表明 CLE 可以开发为哮喘患者的潜在治疗选择。版权所有 © 2024 Elsevier B.V. 版权所有预订的。

Turmeric (Curcuma longa L.) extract (CLE) has been shown to elicit several pharmacological properties and is widely used in Asian traditional medicine. Herein, we assessed the impact of CLE on airway inflammation in BALB/c mice and A549 cells to clarify the underlying mechanism. An asthmatic mouse model was established by administering ovalbumin (OVA). CLE (100 or 300 mg/kg/day) was orally administered daily from days 18 to 23, with dexamethasone (3 mg/kg/day) used as the positive control. Human airway epithelial cells, A549, were stimulated using recombinant tumor necrosis factor-α. The CLE100 and CLE400 groups exhibited a significant downregulation in eosinophil counts, cytokine levels, and immunoglobulin-E levels. Moreover, CLE administration dose-dependently suppressed oxidative stress and airway inflammation in the lung tissue. CLE administration inhibited the phosphorylation of mitogen-activated protein kinases (MAPKs) and the expression and activity of matrix metalloproteinase (MMP)-9. In vitro, CLE treatment reduced mRNA levels of proinflammatory cytokines, MAPK phosphorylation, and the expression and activity of MMP-2 and MMP-9. Additionally, 50 µg/mL CLE and 2.5 µg/mL curcumin showed similar anti-inflammatory effects. Collectively, our findings revealed that CLE could suppress airway inflammation in asthmatic mice and A549 cells via oxidative stress-driven MAPK/MMPs signaling, suggesting that CLE could be developed as a potential treatment option for patients with asthma.Copyright © 2024 Elsevier B.V. All rights reserved.